Brielle Benyon

The Food and Drug Administration (FDA) approved BRACAnalysis CDx to be used to identify patients with advanced ovarian cancer who have germline BRCA mutations and are eligible for first line treatment with Lynparza (olaparib) after responding to platinum-based chemotherapy.

Patients with myeloma who took higher doses of Kyprolis plus dexamethasone tended to have better survival outcomes, according to a recent study.

A person’s relationship with food can change after a cancer diagnosis, stirring up feelings of anxiety. A recent seminar discussed strategies that can help.

Here’s another throwback to one of our 2008 issues, where genetic testing was just gaining steam in the cancer space.

More than 40 percent of patients with a myeloproliferative neoplasm reported that they were unsatisfied with their current pain management strategy.

Take a look at content from CURE Magazine from 10 years ago to see how the myeloma space – and our magazine in general – has changed!

In the general population, African Americans tend to have poorer myeloma outcomes; however, that may not be the case for veterans.

In the MEASURE trial, researchers examined the affect symptom burden associated with myeloproliferative neoplasms has on patients’ lives.

For this episode of the CURE Talks Cancer podcast, we spoke with Scott Hamilton, an Olympic gold medalist, cancer survivor and founder of the Scott Hamilton CARES Foundation

Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.

Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.

Recent research found that some patients with lung cancer have misconceptions about their prognosis, as well as how palliative care can help.

Take a look at the FDA’s decisions for the treatment of SLL that happened this year.

The Food and Drug Administration (FDA) approved Xospata (gilteritinib) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) who have a FLT3 mutation that is detected by an FDA-approved test, according to the agency.

The Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) – the first biosimilar of Rituxan (rituximab) – to treat adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL).

November is Lung Cancer Awareness Month, and our Lung Cancer Special Issue is offering new insights into the treatment of the disease.

A smartphone app helped significantly reduce pain and hospital visits for patients with metastatic solid tumors.

The Food and Drug Administration (FDA) approved Daurismo (glasdegib) plus low-dose cytarabine (LDAC) chemotherapy to treat older, newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for chemotherapy.

A Venclexta combination was granted an accelerated approval to treat older patients with acute myeloid leukemia who are ineligible for chemotherapy.

The Food and Drug Administration (FDA) granted a priority review to quizartinib for the treatment of patients with relapsed or refractory FLT3-ITD acute myeloid leukemia (AML).

An aspirin a day may help keep colorectal cancer at bay, according to recent research.

While CAR-T cell therapy has potential in treating CLL, T-cell fatigue and toxicity still raise many concerns.

CLL is the most common type of leukemia in adults across the United State. Here's what you need to know about the disease.

The Food and Drug Administration (FDA) expedited the approval of Adcetris (brentuximab vedotin) in combination with chemotherapy for certain patients with peripheral T-cell lymphoma (PTCL).

The Food and Drug Administration (FDA) granted a breakthrough therapy designation to Adcetris (brentuximab vedotin) for the frontline treatment of certain lymphoma subtypes, according to Seattle Genetics, the manufacturer of the antibody-drug conjugate.

Two women discuss their experience in cancer caregiving, while giving advice to others.

Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.

Promising results from a recent trial are laying the groundwork for the first change in frontline small cell lung cancer in two decades.

The Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who progressed on one or more ALK tyrosine kinase inhibitor (TKI), according to Pfizer, the drug’s manufacturer.

The immunotherapy agent received approval for the treatment of metastatic squamous non-small cell lung cancer.